MS Patients in UK Now Offered COVID-19 Booster Shots
The U.K.’s National Health Service (NHS) has started its COVID-19 vaccine booster program, offering a third shot — preferably with…
Articles by Marta Figueiredo, PhD
Be Proactive in Managing Bladder, Bowel Problems, Nurses Advise
Bladder and bowel problems, which affect more than half of multiple sclerosis (MS) patients, should be assessed and monitored regularly…
Pro-inflammatory Th17 Immune Cells Harm Myelin-producing Cells
Pro-inflammatory T helper 17 cells, known as Th17 cells — a type of immune cell known to play a role…
T. Gondii Parasite May Protect Against Developing MS
Toxoplasmosis, an infection by the parasite Toxoplasma gondii, has a protective effect against the development of multiple sclerosis (MS), according to a…
National MS Society Invests $8.7M in Research, Clinical Trial Training
The National Multiple Sclerosis Society invested more than $8.7 million over the summer to support 29 new training fellowships,…
Way Seen to Counter Blood-clotting Molecule That Blocks Myelin Repair
Blocking a particular receptor protein of the BMP signaling pathway effectively promoted the maturation of myelin-producing cells and myelin repair…
Top-line Data on NVG-291 in Healthy Volunteers Expected This Year
NervGen Pharma announced that its Phase 1 clinical trial evaluating the safety and pharmacological properties of NVG-291 — its…
MediciNova Planning Phase 3 Trial of Oral Ibudilast for SPMS
MediciNova is planning to launch a Phase 3 clinical trial that will evaluate its investigational oral candidate ibudilast (MN-166)…
Collaboration Explores Therapies for Autoimmune Diseases
Cytocom has joined forces with La Jolla Institute for Immunology (LJI) to discover and develop new immune-modulating therapies targeting…
Ocrevus Effective in RRMS Patients With Poor Responses to Prior DMTs
Ocrevus (ocrelizumab) safely and effectively prevents relapses and disease progression in relapsing-remitting multiple sclerosis (RRMS) patients who responded…
Trial Will Test Mavenclad for Advanced Progressive MS
After some delays due to the COVID-19 pandemic, the Phase 2/3 clinical trial evaluating whether Mavenclad (cladribine) can slow…
Trials Support NfL Levels as Marker of Disease Activity in Relapsing MS
Larger declines with treatment in blood levels of neurofilament light chain (NfL), a marker of nerve cell damage, are associated…
Risk of Severe COVID-19 Not Raised by Immunosuppressive DMTs
Exposure to multiple sclerosis (MS) disease-modifying therapies (DMTs), and particularly immunosuppressive DMTs, does not increase the risk of developing…
Reeve Foundation’s Paralysis Resource Center Given 5-year Grant
The Administration for Community Living (ACL) reaffirmed its support for the work of the National Paralysis Resource Center (PRC)…
Oral CKD-506 Lessens Symptoms, Demyelination in MS Mouse Model
Chong Kun Dang (CKD) Pharmaceutical’s experimental oral therapy CKD-506 suppressed inflammation, myelin loss (demyelination), and lessened symptoms in…
Targeting Ion Channel Piezo1 in T-cells Eased MS in Mice
Removing an ion channel called Piezo1 from immune T-cells lessened disease severity in a mouse model of multiple sclerosis (MS),…
MS-related Fatigue Identified as Main Factor Affecting Work Ability
Fatigue, whether alone or in combination with depression or anxiety, is the main influencing factor of self-reported working ability…
Kesimpta for RRMS Now Available in Scotland at Low or No Cost
Adults in Scotland with active relapsing-remitting multiple sclerosis (RRMS) will now have access at low or no cost to…
Biogen Strikes Deal for Orelabrutinib, Now in Phase 2 Trial
Biogen has signed a deal with InnoCare Pharma to acquire global commercialization and licensing rights to orelabrutinib, an experimental oral…
Scientists ID 2 Brain Cells Likely Involved in Nerve Cell Repair
Researchers have identified a molecular switch that awakens stem cells in a specific region of the mouse brain — and…
Scientists Working on More Efficient Way to Deliver CBD
A team of scientists is working on a new delivery method that would use tiny capsules for getting cannabidoil, or…
MS-related Fatigue Strongly Affects Youngsters’ Functioning
Multiple sclerosis and its associated fatigue negatively affect school performance, mental health, and physical and social functioning in children…
Brainstorm Secures NurOwn-associated Patents in Several Markets
In the past year, BrainStorm Cell Therapeutics was granted four patents and is waiting for a fifth, already accepted,…
Robotic Exoskeleton Intervention Improves Motor, Cognitive Function
Four weeks of robotic exoskeleton-assisted exercise rehabilitation, called REAER, worked better than conventional gait training in improving mobility and cognitive…
Qynapse Announces Research Collaborations for World MS Day
Qynapse, a company that combines artificial intelligence with neuroimaging technology, is reaffirming its commitment to help advance multiple sclerosis…
Walk MS Fundraising Events To Be ‘Virtual Experience’ in 2021
Due to the ongoing COVID-19-associated restrictions, the National Multiple Sclerosis Society is inviting supporters of its Walk MS…
At-home Brain Stimulation Program Now Available
New York University (NYU) Langone Health has launched an at-home, therapeutic program of transcranial direct current stimulation (tDCS) — a…
Mayzent, Zeposia May Lose Ground in Canada, Report Finds
Mayzent (siponimod) and Zeposia (ozanimod), the two sphingosine-1-phosphate (S1P) receptor modulators most recently approved in Canada for treating …
MS May Not Affect Breast Cancer Survival, Study Suggests
Women with multiple sclerosis (MS) diagnosed with breast cancer are not at a higher risk of dying from cancer than…
#AANAM – Blacks, Whites Respond Differently to B-cell Targeting Therapies
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April…